{"id":33484,"date":"2025-05-15T14:16:53","date_gmt":"2025-05-15T06:16:53","guid":{"rendered":"https:\/\/flcube.com\/?p=33484"},"modified":"2025-05-15T14:16:54","modified_gmt":"2025-05-15T06:16:54","slug":"wuhan-hamilton-biotechs-huc-mscs-product-approved-for-clinical-trials-in-premature-ovarian-failure","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33484","title":{"rendered":"WuHan Hamilton Biotech’s HUC-MSCs Product Approved for Clinical Trials in Premature Ovarian Failure"},"content":{"rendered":"\n

China-based WuHan Hamilton Biotechnology Co., Ltd. has announced receiving clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 biologic product: human umbilical cord mesenchymal stem cells (HUC-MSCs) for the treatment of premature ovarian failure. This marks a significant milestone as the product becomes the first of its kind cleared for study in this indication in China.<\/p>\n\n\n\n

Premature Ovarian Failure and Its Challenges<\/strong>
Premature ovarian failure is a condition characterised by menstrual abnormalities, elevated levels of gonadotropins, fluctuating levels of estrogen, and is often accompanied by cardiovascular and neurodegenerative diseases. This approval opens the door to potential new therapies for patients suffering from this complex condition.<\/p>\n\n\n\n

Hamilton Bio’s HUC-MSCs Product Mechanism<\/strong>
Hamilton Bio\u2019s HUC-MSCs product offers a novel approach to treating premature ovarian failure. It works by partially restoring ovarian structure and function, thereby improving patients’ quality of life. The product achieves this by inhibiting apoptosis, promoting the proliferation of ovarian granulosa cells, and suppressing local inflammatory reactions within ovarian tissue.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based WuHan Hamilton Biotechnology Co., Ltd. has announced receiving clinical trial approval from the National…<\/p>\n","protected":false},"author":1,"featured_media":33488,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[77,62,4075],"class_list":["post-33484","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cell-therapy","tag-clinical-trial-approval-initiation","tag-hamilton-biotechnology"],"yoast_head":"\nWuHan Hamilton Biotech's HUC-MSCs Product Approved for Clinical Trials in Premature Ovarian Failure - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based WuHan Hamilton Biotechnology Co., Ltd. has announced receiving clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 biologic product: human umbilical cord mesenchymal stem cells (HUC-MSCs) for the treatment of premature ovarian failure. This marks a significant milestone as the product becomes the first of its kind cleared for study in this indication in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33484\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"WuHan Hamilton Biotech's HUC-MSCs Product Approved for Clinical Trials in Premature Ovarian Failure\" \/>\n<meta property=\"og:description\" content=\"China-based WuHan Hamilton Biotechnology Co., Ltd. has announced receiving clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 biologic product: human umbilical cord mesenchymal stem cells (HUC-MSCs) for the treatment of premature ovarian failure. This marks a significant milestone as the product becomes the first of its kind cleared for study in this indication in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33484\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-15T06:16:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-15T06:16:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1505.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33484#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33484\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"WuHan Hamilton Biotech’s HUC-MSCs Product Approved for Clinical Trials in Premature Ovarian Failure\",\"datePublished\":\"2025-05-15T06:16:53+00:00\",\"dateModified\":\"2025-05-15T06:16:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33484\"},\"wordCount\":184,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33484#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1505.webp\",\"keywords\":[\"Cell-therapy\",\"Clinical trial approval \\\/ initiation\",\"Hamilton Biotechnology\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33484#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33484\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33484\",\"name\":\"WuHan Hamilton Biotech's HUC-MSCs Product Approved for Clinical Trials in Premature Ovarian Failure - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33484#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33484#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1505.webp\",\"datePublished\":\"2025-05-15T06:16:53+00:00\",\"dateModified\":\"2025-05-15T06:16:54+00:00\",\"description\":\"China-based WuHan Hamilton Biotechnology Co., Ltd. has announced receiving clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 biologic product: human umbilical cord mesenchymal stem cells (HUC-MSCs) for the treatment of premature ovarian failure. This marks a significant milestone as the product becomes the first of its kind cleared for study in this indication in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33484#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33484\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33484#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1505.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1505.webp\",\"width\":1080,\"height\":608,\"caption\":\"WuHan Hamilton Biotech's HUC-MSCs Product Approved for Clinical Trials in Premature Ovarian Failure\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33484#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"WuHan Hamilton Biotech’s HUC-MSCs Product Approved for Clinical Trials in Premature Ovarian Failure\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"WuHan Hamilton Biotech's HUC-MSCs Product Approved for Clinical Trials in Premature Ovarian Failure - Insight, China's Pharmaceutical Industry","description":"China-based WuHan Hamilton Biotechnology Co., Ltd. has announced receiving clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 biologic product: human umbilical cord mesenchymal stem cells (HUC-MSCs) for the treatment of premature ovarian failure. This marks a significant milestone as the product becomes the first of its kind cleared for study in this indication in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33484","og_locale":"en_US","og_type":"article","og_title":"WuHan Hamilton Biotech's HUC-MSCs Product Approved for Clinical Trials in Premature Ovarian Failure","og_description":"China-based WuHan Hamilton Biotechnology Co., Ltd. has announced receiving clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 biologic product: human umbilical cord mesenchymal stem cells (HUC-MSCs) for the treatment of premature ovarian failure. This marks a significant milestone as the product becomes the first of its kind cleared for study in this indication in China.","og_url":"https:\/\/flcube.com\/?p=33484","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-15T06:16:53+00:00","article_modified_time":"2025-05-15T06:16:54+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1505.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33484#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33484"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"WuHan Hamilton Biotech’s HUC-MSCs Product Approved for Clinical Trials in Premature Ovarian Failure","datePublished":"2025-05-15T06:16:53+00:00","dateModified":"2025-05-15T06:16:54+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33484"},"wordCount":184,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33484#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1505.webp","keywords":["Cell-therapy","Clinical trial approval \/ initiation","Hamilton Biotechnology"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33484#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33484","url":"https:\/\/flcube.com\/?p=33484","name":"WuHan Hamilton Biotech's HUC-MSCs Product Approved for Clinical Trials in Premature Ovarian Failure - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33484#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33484#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1505.webp","datePublished":"2025-05-15T06:16:53+00:00","dateModified":"2025-05-15T06:16:54+00:00","description":"China-based WuHan Hamilton Biotechnology Co., Ltd. has announced receiving clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 biologic product: human umbilical cord mesenchymal stem cells (HUC-MSCs) for the treatment of premature ovarian failure. This marks a significant milestone as the product becomes the first of its kind cleared for study in this indication in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33484#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33484"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33484#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1505.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1505.webp","width":1080,"height":608,"caption":"WuHan Hamilton Biotech's HUC-MSCs Product Approved for Clinical Trials in Premature Ovarian Failure"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33484#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"WuHan Hamilton Biotech’s HUC-MSCs Product Approved for Clinical Trials in Premature Ovarian Failure"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1505.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33484","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33484"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33484\/revisions"}],"predecessor-version":[{"id":33489,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33484\/revisions\/33489"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33488"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33484"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33484"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33484"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}